CurrentBlue Cross Blue Shield - MassachusettsPolicy N/A

Wearable cardioverter-defibrillator (WCD) coverage — coverage criteria

Defines medical necessity and coverage conditions for wearable cardioverter-defibrillators (WCDs/K0606) for Commercial and Medicare products and describes when WCD use is investigational.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyWearable cardioverter-defibrillator (WCD) coverage — coverage criteria

Policy CodePolicy N/A

Change TypeNo material change noted

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization when services are performed inpatient; outpatient prior authorization varies by product.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

K0606Primary HCPCS code

1 RCTRandomized trial evidence

no shocksRegistry no shocks (~124 d)

4 shocksCohort study shocks (133 d)

annualPolicy reviews

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Wearable Cardioverter-Defibrillators (WCD)

Covered indications (Commercial Members)

Covered when ANY of the following high‑risk conditions are met:

Covered when ANY of the following are met

1) Familial/inherited high‑risk conditions: Familial or inherited conditions with a high risk of life‑threatening ventricular tachyarrhythmia (examples: long QT syndrome, hypertrophic cardiomyopathy).
2) Documented ventricular fibrillation or sustained ventricular tachyarrhythmia: A documented episode of ventricular fibrillation or a sustained ventricular tachyarrhythmia lasting ≥ 30 seconds (spontaneous or induced during electrophysiologic study), provided the event is not due to a transient or reversible cause and did not occur during the first 48 hours of an acute myocardial infarction.ventricular tachyarrhythmia duration >= 30 seconds
3) Prior MI or dilated cardiomyopathy with reduced LVEF: Documented prior myocardial infarction or dilated cardiomyopathy with measured left ventricular ejection fraction ≤ 0.35.LVEF <= 0.35
4) Previously implanted defibrillator explanted: Patient had a previously implanted defibrillator that now requires explantation (eg, infected device requiring removal).

ref”:

title”:

Temporary contraindication to ICD (Bridge therapy)

Covered when ALL of the following are met:

Covered when ALL of the following are met: Patient meets established indications for an implantable cardioverter‑defibrillator but currently has a transient contraindication to ICD implantation (for example, an active device‑related infection). The WCD is being used as a bridge to definitive ICD placement or to clinical improvement that would permit later ICD implantation.temporary contraindication present

Evidence cited supports that the WCD can detect lethal arrhythmias and successfully deliver therapy as an interim treatment; ordering clinician should document planned timing for transition to ICD when clinically appropriate.

Evidence-based coverage conclusion

Summary coverage stance based on the evidence reviewed:

Overall evidence conclusion: The evidence is insufficient to determine that WCD use improves net health outcomes for patients with newly diagnosed nonischemic cardiomyopathy or peripartum cardiomyopathy under the conditions studied. Conversely, for patients with a transient contraindication to an ICD (bridge therapy), the evidence is sufficient to support WCD use as an interim treatment.

RCT evidence showed no mortality benefit for prophylactic ICD in nonischemic cardiomyopathy; registry and cohort data for WCD in peripartum cardiomyopathy reported few or no appropriate shocks and are inadequate to demonstrate improved outcomes.

Use of wearable cardioverter-defibrillators (WCDs, HCPCS code K0606) is considered investigational for all indications not explicitly listed as covered. This investigational designation applies to any use beyond the specified high‑risk groups (familial/inherited arrhythmia syndromes, documented ventricular fibrillation or sustained ventricular tachyarrhythmia ≥30 seconds not due to a reversible cause and not occurring during the first 48 hours of an acute MI, prior MI or dilated cardiomyopathy with measured LVEF ≤ 0.35 (≤ 35%), and prior ICD explantation).

The policy does not enumerate procedural or diagnosis‑based exclusions beyond the covered indications; no specific operations or diagnosis codes are singled out as automatically excluded in the source text. However, absence of explicit supporting evidence for a given procedure or diagnosis should be interpreted cautiously: where evidence is lacking or insufficient to demonstrate benefit, the policy treats those uses as investigational and not routinely covered. Claims for indications without supporting evidence therefore carry risk of denial under the investigational-use policy language.

Evidence for WCD use in several specific populations is limited and inconsistent. In the immediate post‑myocardial infarction period an RCT showed no benefit of WCD over guideline‑based care and cohort and systematic review data were low to very low quality; overall evidence was judged insufficient to demonstrate improved net health outcome. For high‑risk post‑CABG patients, randomized data for prophylactic ICD placement also showed no survival benefit and registry data for WCD were unable to provide definitive conclusions; evidence is insufficient to support routine WCD use. For patients awaiting heart transplantation the available registry and cohort analyses do not provide adequate data to conclude benefit; WCD use as a bridge to transplant remains unsupported by high‑quality comparative evidence.

Evidence is currently insufficient to support WCD use for newly diagnosed nonischemic cardiomyopathy and for peripartum cardiomyopathy. An RCT examining prophylactic ICD placement in nonischemic cardiomyopathy showed no mortality benefit, and retrospective registry analyses of WCD use did not demonstrate improved outcomes—therefore WCD is not expected to improve outcomes under the studied conditions. For peripartum cardiomyopathy, a registry reported no shocks over an average of ~124 days while a small cohort observed 4 appropriate shocks over 133 days; these limited and inconsistent findings do not establish that WCD use improves net health outcomes in these populations.

Coding (HCPCS, ICD-10) and Related Values

HCPCS Codes (WCD and accessories)HCPCS

K0606	Wearable cardioverter-defibrillator (WCD) (primary code referenced in policy)
K0607	Automatic external defibrillator with integrated electrocardiogram analysis, garment type
K0608	Replacement battery for automated external defibrillator, each

Selected ICD-10 Diagnosis Codes referencedICD-10

I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery
I21.02	STEMI involving left anterior descending coronary artery
I42.0	Dilated cardiomyopathy
I45.81	Long QT syndrome
I46.2	Cardiac arrest due to underlying cardiac condition
I47.2	Ventricular tachycardia
I49.01	Ventricular fibrillation

Coding and coding clarificationsmixed

No codes listed

Left ventricular ejection fraction (LVEF) — thresholds

LVEF thresholdLeft ventricular ejection fraction ≤ 0.35 (≤ 35%) referenced for prior myocardial infarction or dilated cardiomyopathy

Context of thresholdApplies when documented prior MI or dilated cardiomyopathy are present as one of the covered indications for WCD

Related clinical noteOrdering physician expected to be experienced in management of patients at risk for sudden cardiac death

Average days of device use reported in studies

Registry average wear durationApproximately 124 days (no shocks delivered during this registry period)

Cohort study average wear duration133 days (cohort reported 4 appropriate shocks over this period)

Evidence implicationRegistry and cohort durations reported but evidence was judged insufficient to determine net health benefit for peripartum or newly diagnosed nonischemic cardiomyopathy

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Preauthorization (precertification) is required for services described in this policy when performed in the inpatient setting. Providers must obtain prior authorization before inpatient procedures to ensure coverage.

Applies to all products when procedure is inpatient

Prior Authorization

Prior Authorization — Outpatient Variability

For outpatient services, prior authorization rules vary by product. For some Commercial products (PPO and Indemnity) outpatient prior authorization may not be required; providers should verify plan-level requirements prior to scheduling.

Commercial PPO and Indemnity — outpatient prior authorization not required in some cases; verify member contract

Documentation Required

Documentation and Coding Requirements

Providers must document medical necessity in the medical record and report all services using the most up-to-date CPT, HCPCS, revenue, and ICD-10 codes (including modifiers and current procedure codes). Maintain documentation to support the necessity and frequency of services and to align with coding clarifications in the policy history.

Report services using current CPT/HCPCS/ICD-10 codes and applicable modifiers
Document medical necessity and clinical rationale in the member's chart
Retain records consistent with coding clarifications in policy history

Documentation Required

Maintain Documentation Consistent with Coding Clarifications

Providers should be aware that coding guidance in the policy history has been updated periodically. Align claim submissions and clinical documentation with the latest coding clarifications to avoid processing delays or denials.

Refer to Policy History for coding clarification dates (e.g., 10/2022, 1/2018, 12/2016, 9/2015)
Ensure claims reflect updated codes referenced in the policy history

Step Therapy

Step therapy requirements are not specified in the provided policy content. If step therapy applies, it will be stated at the plan level; providers should check the member's benefit program for any step requirements before ordering.

No step therapy specified in this partial document
Check member's contract/plan for any step therapy rules

Denial Risk

Investigational-Use Denial Risk

Use of the wearable cardioverter-defibrillator (WCD) for indications not supported by the evidence in this policy may be considered investigational; claims for investigational or non‑medically necessary indications may be denied.

WCD considered investigational for indications not listed as medically necessary
Claims for investigational indications are at risk of denial

Denial Risk

Insufficient Evidence May Lead to Denial

Evidence is insufficient for certain clinical scenarios (for example, newly diagnosed nonischemic cardiomyopathy and peripartum cardiomyopathy) to conclude that WCD improves net health outcomes. Services in these situations may be denied as not medically necessary.

Examples of insufficient evidence: newly diagnosed nonischemic cardiomyopathy; peripartum cardiomyopathy
Registry and small cohort data do not establish improved outcomes

Definitions

Wearable cardioverter-defibrillator (WCD) — definition and device description

DefinitionA wearable cardioverter-defibrillator (WCD) is an external vest-based device worn under clothing that contains monitoring and therapy electrodes connected to a monitor which interprets cardiac rhythm and delivers counter shocks when necessary

ComponentsVest with electrode belt, monitor with battery pack and alarm module worn on the patient's belt

Indication summaryIntended as a temporary, noninvasive alternative to an implantable cardioverter-defibrillator for patients not candidates for or refusing an ICD or with transient contraindications

Sudden cardiac arrest (SCA) — definition and clinical note

DefinitionSudden cardiac arrest (SCA) is an abrupt loss of heart function, most commonly due to ventricular arrhythmias, and is a leading cause of death in patients with coronary artery disease

Clinical noteImplantable cardioverter-defibrillators reduce mortality for survivors of SCA and for patients with documented malignant ventricular arrhythmias

Relevance to WCDWCDs are intended to detect and terminate ventricular arrhythmias to protect against SCA in temporary or high‑risk situations

WCD — short definition

Short definitionWCD: an external, temporary device worn to detect and terminate ventricular arrhythmias as an alternative to an implantable ICD

Usage notePrimarily intended for temporary conditions when an implantable device is contraindicated or when need for a permanent device is uncertain

Device form factorVest-based system with monitoring and therapy electrodes connected to a monitor and alarm module

Peripartum cardiomyopathy — definition and association

DefinitionPeripartum cardiomyopathy: a nonischemic cardiomyopathy presenting in the peripartum period (during pregnancy or shortly after delivery) associated with left ventricular dysfunction and risk for arrhythmia

Evidence summaryEvidence for WCD use in peripartum cardiomyopathy includes a retrospective registry (no shocks over ~124 days) and a small cohort (4 appropriate shocks over 133 days); evidence deemed insufficient to demonstrate improved net health outcomes

Clinical implicationBecause evidence is insufficient, WCD use for peripartum cardiomyopathy is not established as improving outcomes under studied conditions

OpenPayer

Wearable cardioverter-defibrillator (WCD) coverage — coverage criteria

Coverage Criteria for Wearable Cardioverter-Defibrillators (WCD)

Coding (HCPCS, ICD-10) and Related Values

Provider Actions, Prior Authorization, and Documentation

Background

Definitions